疫苗ETF（159643）跟踪的是疫苗生科指数（980015），该指数从市场中选取涉及疫苗研发、生产、销 售以及生物科技相关业务的上市公司证券作为指数样本，以反映疫苗及生物科技行业上市公司证券的整 体表现。该指数聚焦生物科学领域前沿，重点覆盖具有创新技术能力和产业化优势的疫苗企业，能够有 效体现行业技术发展趋势和市场动态。 1月5日，疫苗ETF（159643）涨超1.7%，创新兑现与全球布局成行业焦点 东海证券指出，医药生物行业正经历结构性变革。医疗器械行业在经历反腐、集采等压力后，随着院内 招投标活跃和政策优化，2026年有望进入新增长周期，海外市场成为重要增量。创新药领域已进入"大 时代"，2026年将主导行业，医保商保结合打开支付空间，CXO及上游产业链保持良好增长。医疗服务 消费受益于政策优化和需求升级，专科医院及连锁药店优势显现。医疗器械板块呈现"政策出清—创新 突围—出海扩张"趋势，AI、脑机接口等技术推动高端设备出口增长。药店行业结束高速扩张，转向质 量优化，龙头通过多元化经营巩固地位。整体来看，行业在政策出清和技术创新驱动下步入新阶段，但 需关注集采、研发失败等风险。 风险提示：提及个股仅用于 ...

Group 1 - The core viewpoint of the news highlights the significant increase in vaccine-related activities, with a reported 2,934 confirmed cases of Kikenya fever in Shunde District, Guangdong, primarily in Lecong, Beijiao, and Chen Village, all classified as mild cases [1] - The number of clinical trial applications and market approvals for vaccines in the first half of 2025 has shown rapid growth, with 45 clinical trial applications and 12 market approvals, totaling 57 applications, representing a year-on-year increase of 58.3% [1] - The growth in vaccine applications is driven by high-demand products, with influenza and shingles vaccines leading the submissions, each with 11 applications, and a notable increase in the development of recombinant and mRNA vaccines [1] Group 2 - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which includes listed companies involved in vaccine research, production, and related biotechnology businesses, reflecting the overall performance of the vaccine industry [2] - The index is compiled by China Securities Index Co., Ltd., focusing on the biopharmaceutical sector, particularly the vaccine and biotechnology fields [2]

Group 1 - The TCE technology sector is experiencing a significant breakthrough, particularly in the treatment of autoimmune diseases, with CD3T cell connectors showing notable therapeutic potential [1][2] - TCE drugs offer advantages such as precise targeting of pathological cells, reduced toxicity through controlled CD3 co-stimulation signals, and engineered adjustments to prolong efficacy [1] - The global interest in TCE technology has surged in 2024, with total transaction amounts reaching approximately $4.3 billion, indicating a rising trend in high-value TCE deals among biotech companies [2] Group 2 - Notable transactions include Merck's acquisition of Tongrun Biotech's CD3/CD19 bispecific antibody product for $1.3 billion, and AbbVie’s agreement with IGITherapeutics for exclusive rights to ISB2001, involving a $700 million upfront payment [2] - The vaccine ETF (code: 159643) tracks the vaccine biotech index (code: 980015), reflecting the overall performance of listed companies involved in vaccine research and production [2] - Investors without stock accounts can consider the linked ETFs, such as Guotai Guozheng Vaccine and Biotechnology ETF [2]

Group 1 - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, proposing 16 comprehensive support policies [1] - The government emphasizes the importance of pharmaceutical innovation, with plans to establish a commercial health insurance directory for innovative drugs by 2025 [1] - The measures allow the use of healthcare insurance data for innovative drug research and development, promoting genuine and differentiated innovation [1] Group 2 - The time for innovative drugs to enter the healthcare insurance system has significantly decreased, now averaging around one year from approval to inclusion, with approximately 80% of innovative drugs included within two years of market launch [1] - The commercial health insurance market is rapidly growing, with projected premium income reaching 977.3 billion yuan in 2024, reflecting an 8.2% year-on-year increase [1] - The measures propose 16 initiatives across five areas, including research support, healthcare insurance access, and clinical application, to foster the high-quality development of innovative drugs [1] Group 3 - The Vaccine ETF tracks the Vaccine Biotechnology Index, which includes listed companies involved in vaccine research, production, sales, and biotechnology, covering all aspects of the vaccine industry chain [2] - The index aims to reflect the overall performance of listed companies in China's vaccine and biotechnology sector, showcasing its professionalism and growth characteristics [2]